Ropinirole for restless legs syndrome: a placebo-controlled crossover trial.

Author(s): Adler CH, Hauser RA, Sethi K, Caviness JN, Marlor L, Anderson WM, Hentz JG

Affiliation(s): Parkinson's Disease and Movement Disorders Center, Mayo Clinic Scottsdale, AZ 85259, USA. cadler@mayo.edu

Publication date & source: 2004-04-27, Neurology., 62(8):1405-7.

Publication type: Clinical Trial; Randomized Controlled Trial

The authors performed a double-blind, placebo-controlled, crossover study of ropinirole (0.5 to 6.0 mg/day) for restless legs syndrome (RLS). The RLS Rating Scale score improved (p < 0.001) from a mean (SD) of 25 (7) during placebo treatment to 13 (12) during ropinirole treatment. Eight of the 22 patients had complete resolution of symptoms on ropinirole. Adverse events included nausea and dizziness. Ropinirole was effective and well tolerated for treating the symptoms of RLS.